In May 2022, tirzepatide was approved by the US FDA to improve blood glucose in adults with type 2 diabetes
In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
In patients with cirrhosis, low testosterone levels frequently lead to muscle wasting and increased fat deposition, which further exacerbates liver disease progression
This approach aims to empower the patient with information regarding the different aspects of available treatment options, including flexibility, complexity, route, and frequency of administration